Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Weizmannia Coagulans BC99 Relieves Constipation Symptoms by Regulating Inflammatory, Neurotransmitter, and Lipid Metabolic Pathways: A Randomized, Double-Blind, Placebo-Controlled Trial

NCT06637397 is registered in ClinicalTrials.gov with Wecare Probiotics Co., Ltd. as lead sponsor.

NCT NCT06637397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06637397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Weizmannia Coagulans BC99 Relieves Constipation Symptoms by Regulating Inflammatory, Neurotransmitter, and Lipid Metabolic Pathways: A Randomized, Double-Blind, Placebo-Controlled Trial
Lead sponsor
Wecare Probiotics Co., Ltd.
Phase
Not applicable
Overall status
Completed
Start date
July 4, 2024
Completion date
October 20, 2024
Enrollment
100 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

constipation